A Case of Graft-Versus-Host Disease in a Liver Transplant Recipient Receiving an HCV NAT Positive Organ: Does HCV NAT Matter? (PubMed, Transplant Proc) - Sep 27, 2026 - "Treating GVHD with ruxolitinib and HCV with glecaprevir/pibrentasvir simultaneously is both effective and safe."
Journal • Bone Marrow Transplantation • Graft versus Host Disease • Hepatology • Immunology • Solid Organ Transplantation • Transplantation
|